Skip to content
Share

|

eAlerts

|

Register

|

Login
  • Services
    • News Services
    • Conference Coverage & Reporting
    • Expert Interviews & Discussion
    • Featured Content Creation
    • Multimedia
  • Specialties
  • Showcase
  • Clients
  • News & Insights
  • About
  • Contact

Day: February 10, 2025

OS benefits with perioperative FLOT for resectable oesophageal cancer

Esophageal cancer, 3D illustration showing malignant tumor in the human esophagus

Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel offers better overall survival than preoperative chemoradiotherapy for patients with locally advanced oesopahgeal adenocarcinoma, the ESOPEC trial investigators report.

Building relationships through trusted content for healthcare professionals

GET STARTED
A global leader in medical content

© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.

Twitter Icon-social_rss
Social Share
Contact
eAlerts
Register
Login
Terms of Use
Privacy Policy
Cookie Policy